What are Insulin combination product drugs?

Insulin combination product drugs are pharmacologic agents that share a common mechanism (typically targeting Insulin receptor). 5 are currently marketed, with 0 more in clinical development.

What are the marketed Insulin combination product drugs?

Marketed Insulin combination product drugs include Lispro mix 75/25, Humalog Mix 75/25, premix insulin, Insulin Lispro Mix25, Lispro Low Mix.

Insulin combination product

5 marketed

This page covers all Insulin combination product drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Insulin receptor.

Targets

Insulin receptor

Marketed (5)

Lispro mix 75/25 · Eli Lilly and Company · Diabetes
Lispro mix 75/25 is a combination insulin that provides rapid-acting insulin coverage for mealtime glucose spikes plus intermediate-acting basal insulin for baseline glucose control.
Humalog Mix 75/25 · Biodel · Diabetes
Humalog Mix 75/25 is a combination insulin product that provides both rapid-acting and intermediate-acting insulin to control blood glucose levels in diabetes.
premix insulin · Shanghai 6th People's Hospital · Diabetes
Premix insulin is a combination of rapid-acting and intermediate-acting insulin that replaces or supplements the body's natural insulin to regulate blood glucose levels.
Insulin Lispro Mix25 · Eli Lilly and Company · Diabetes
Insulin Lispro Mix25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells.
Lispro Low Mix · Eli Lilly and Company · Diabetes
Lispro Low Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.